Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorZeiser, Robert
dc.contributor.authorRusso, Domenico
dc.contributor.authorRam, Ron
dc.contributor.authorHashmi, Shahrukh K.
dc.contributor.authorChakraverty, Ronjon
dc.contributor.authorMiddeke, Jan Moritz
dc.contributor.authorMusso, Maurizio
dc.contributor.authorGiebel, Sebastian
dc.contributor.authorUzay, Ant
dc.contributor.authorLangmuir, Peter
dc.contributor.authorHamad, Nada
dc.contributor.authorLi, Xuechan
dc.contributor.authorGowda, Maanasa
dc.contributor.authorStefanelli, Tommaso
dc.contributor.authorLee, Stephanie J.
dc.contributor.authorTeshima, Takanori
dc.contributor.authorLocatelli, Franco
dc.date.accessioned2025-10-16T15:14:10Z
dc.date.issued2023
dc.description.abstract65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 09-12, 2023
dc.identifier.doi10.1182/blood-2023-172590
dc.identifier.otherWOS:001159306702167
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6083
dc.publisherELSEVIER
dc.sourceBLOOD
dc.titleRuxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS